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Abstract
Background: Crohn's disease (CD) and ulcerative colitis (UC), widely known as inflammatory
bowel diseases (IBD), are thought to result from an inappropriate activation of the mucosal
immune system driven by intestinal bacterial flora.
Methods: Although the extraintestinal manifestations of IBD are well documented, the
association of IBD with neurologic and neuromuscular involvement is rare and often
controversial, with sporadic and conflicting data on its prevalence and spectrum. In addition,
a serious number of the latter manifestations may become life-threatening, playing a very
important role in disease morbidity. To define the pattern of neurologic involvement in IBD, the
most important manifestations in these patients have been reviewed, exploring also their clinical
significance.
Results: There is evidence that UC and CD can manifest both in the PNS and CNS. Thrombotic
complications are common in IBD patients, but cerebral vascular involvement is rare.
Conclusions: Neurologic manifestations in IBD patients are more common than previously
estimated and may follow a different pattern of involvement in CD and UC. Small numbers of
patients currently preclude a better characterization of the clinical spectrum and a better
understanding of pathogenesis.
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Inflammatory bowel diseases (IBD), which include Crohn's
disease (CD) and ulcerative colitis (UC) have a worldwide
distribution and are common causes of gastrointestinal
morbidity in Western Europe and Northern America. Recent
population based studies suggest that the combined preva-
lence of these diseases in Western countries approaches 400
per 100,000.1
The extraintestinal manifestations of IBD, however, are
not of less importance. In some cases they are the first
clinical manifestation of the disease and may precede the
onset of gastrointestinal symptoms by many years. As
multisystemic diseases, IBD, have been correlated with
many other organs, including the skin, eyes, joints, bone,
blood, kidney, liver and biliary tract. Neurologic and
neuromuscular complications have also been reported, but
the real incidence of these complications is unknown, with
reports varying from 0.25 to 35.7%; the variation could be
due to selection bias or to different disease definitions.2–5
Although there is increasing evidence that IBD may
manifest in the nervous system, a reliable differentiation
may clinically not always be possible. More analytically,
disorders of the peripheral and central nervous system in
association with IBD can be ascribed to at least six different
mechanisms, which may be present in isolation or in
combination: (i) malabsorption and nutritional, particularly
vitamin deficiencies such as B1, B12, D, E, folic acid and
nicotinamide deficiencies (ii) metabolic agents, (iii) infec-
tions as a complication of immunosuppression, (iv) side
effects of medications (metronidazole, sulfasalazine, ster-
oids, cyclosporine A) or iatrogenic complications of surgery,
(v) thromboembolism, (vi) immunological abnormalities. In
addition to these — at least theoretically — clearly defined
and distinct etiologies, neurologic signs and symptoms may
also be due to a so far speculative and not further specified
neuronal influence of enteric disease onto the nervous
system (and vice versa). Such a hypothesis may be derived
from contemporary theories considering the existence of a
‘brain-gut axis’, and from results of respective functional
neuroimaging studies.6–8 The interactions between the brain
and the gut are illustrated by the role of stress in IBD. This
interaction has been demonstrated in many animal experi-
ments and in some controlled observations in patients with
IBD.9,10 No longer is stress considered to be an etiological
factor in causing the disease, but, rather, stress appears to
be a factor contributing to the exacerbation of the disease.
Stress is perceived by the central nervous system (CNS) in
very specific locations, such as the hypothalamus. The CNS is
then able to modulate the degree of inflammation of the
bowel through multiple routes including neural and neuro-
endocrine pathways, the hypothalamic-pituitary-adrenalaxis, the release of corticotropin-releasing-factor and its
effects on adrenal-corticoid secretion, the autonomic
nervous system and systemic stimulation or suppression of
immune functions. The multiplicity of pathways by which the
brain affects the gut makes it very difficult to study and to
modulate the system pharmacologically.11 In addition,
myenteric plexitis seems to have a highly predictive value
in IBD recurrence and endoscopic severity.12
The paper is a complete and extensive review of the
following PubMed key words: neurologic manifestations and
IBD, neurologic manifestations and inflammatory bowel
diseases, extra-intestinal manifestations in IBD. Table 1a
and 1b contains the most commonly reported neurologic and
neuromuscular IBD manifestations, even if the level of
evidence relies partly on single case reports. Fig. 1 sum-
marizes the pathophysiologic mechanisms for PNS and CNS
neuropathy in IBD patients.1.1. Peripheral neuropathy
Peripheral neuropathy (PN) is one of the most frequently
reported neurological complications in IBD patients.2,5
Several different PN phenotypes have been described in
these patients. Paraesthesias due to small fibre involvement
(autonomic or sensory) and increased threshold for temper-
ature detection (or axonal sensory findings which could be
indicative for early PN) are common in patients with CD who
have been treated with metronidazole (21–39%), but also in
those who have not received this medication (19%).13 In a
retrospective study of patients with PN and either CD or UC,
conducted by Gondim et al.,14 it was demonstrated that PN
symptoms began earlier in the course of CD than in UC
(pb0.05). In the same study it was shown that men with IBD
may be more susceptible to the development of PN than
women, but the latter may be more prone to demyelinating
neuropathies (chronic inflammatory demyelinating poly-
neuropathy or multifocal motor neuropathy). Finally, it was
concluded that even if axonal neuropathies are more
common than demyelinating neuropathies, both can respond
well to immunomodulatory therapy. The concept that PN
manifesting in IBD is probably autoimmune-induced is
strongly supported by further reports, describing recovery
after initiation of steroid treatment.151.2. Drug induced neurotoxicity
Drug induced neuropathy has been ascribed to at least four
different medications, commonly used in the treatment of
IBD: (i) cyclosporine A (ii) metronidazole, (iii) sulfasalazine
(iv) biological agents.
Table 1a Neurologic manifestations reported in IBD.
Manifestation Reference number IBD type Comment
Seizure disorder (generalized tonicoclonic,
complex or simple partial, multiple)
2 CD Mainly with active disease
63 UC Active disease
82 UC Active disease
Cerebrovascular accident (infarct-ischemic) 5 CD and UC Mainly with active disease
8 UC Active disease
60 CD Not defined
69 CD and UC Active disease
Peripheral neuropathy (axonal) 2 CD Mainly with active disease
5 UC Mainly with active disease
15 UC Active disease
Increased reflexes with tremor 2 CD Mainly with active disease
Brachial neuritis 2 CD Mainly with active disease
Optic neuropathy 50 CD Disease in remission
51 UC Active disease
52 CD Active disease
Cranial nerve palsies 2 CD Mainly with active disease
44 CD Active disease
46 CD Active disease
47 CD Active disease
Prolapsed nucleus pulposus 2 CD Mainly with active disease
Parkinson or Parkinson-like syndrome 2 CD Mainly with active disease
Cerebellar syndrome or organic brain syndrome 2 CD Mainly with active disease
Classic migraine 2 CD Mainly with active disease
Atypical cerebellar disorders 2 CD Mainly with active disease
Atypical vestibular system disorders(vertigo,
loss of equilibrium, etch)
8 UC Active disease
Acute inflammatory demyelinating
neuropathy (antiTNFα)
34 CD Active disease
35 CD Active disease
36 CD Active disease
MS 8 UC Not defined
76 CD Disease in remission
77 CD Disease in remission
78 CD Active disease
79 CD Active disease
Sensorineural hearing loss 105 CD Active disease
106 CD and UC Mainly with active disease
107 UC Disease in remission
108 UC Active disease
Myeloradiculopathy 102 UC Active disease
103 UC Disease in remission
SEA 100 CD Active disease
101 CD Active disease
CNS tumors 2 CD Occasional exacerbations
Urinary incontinence 2 CD Occasional exacerbations
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interferes with the transcription of cytokines, thus inhibiting
the activation and maturation of various cell types involved in
cell-mediated immunity. It is mainly used in the treatment of
steroid-refractory acute severe UC. Clinical presentation of
neurotoxicity, which occurs up to 25% of CyA users, includes
seizures, tremors, paraesthesias, ataxias, motor deficits,
aphasia, altered consciousness and various degrees of visual
and oculomotor disturbances. Pathogenesis of the central
nervous system toxicity is poorly understood. CyA-induced
visual disturbances such as hallucinations, cortical blindness
and oculomotor disturbances, are extremely rare complica-tions that have beenwell documented before.16 Porges Y et al.
reported a case of CyA-induced optic neuropathy, opthalmo-
plegia and nystagmus in a patient with CD.17 The reported
patient developed severe visual loss caused by irreversible
bilateral optic neuropathy, clinically compatiblewith ischemic
optic neuropathy. Although the pathogenesis of optic neurop-
athy in the reported patient was not clear, possible mechan-
isms that have been involved include direct toxicity to
peripheral nerves or indirect effect through thromboembolic
phenomena leading to ischemic optic neuropathy. Although
thromboembolic events during CyA therapy have been
detected in branches of the retinal artery, the mechanism
Table 1b Neuromuscular and other manifestations
reported in IBD.
Manifestation Reference
number
IBD
type
Comment
Granulomatous myositis
and myopathy
92 CD Active disease
93 CD Active disease
94 UC Disease in
remission
96 CD Active disease
MG 2 CD Occasional
exacerbations
84 CD Active disease
85 UC Disease in
remission
86 UC Active disease
87 UC Active disease
88 UC Active disease
Orbital pseudotumor 2 CD Occasional
exacerbations
Muscle spasms 2 CD Occasional
exacerbations
Chronic back pain 2 CD Occasional
exacerbations
Tension headache–
musculoskeletal
headache
2 CD Occasional
exacerbations
Chronic fatigue syndrome 2 CD Occasional
exacerbations
118 C.D. Zois et al.formation remains unknown.18 Nystagmus was probably of
cerebellar origin in the mentioned patient because he had
demonstrated both appendicular and truncal ataxia accompa-
nied by cerebellar atrophy, which was disclosed on MRI
examination. Cerebellar atrophy and toxicity have been
reported during CyA treatment, sometimes with hypomagne-
semia.19 However, CyA-induced neurotoxicity has been
described during treatment of CD even in the absence of
previously reported biochemical (hypocholesterolemia, hypo-
magnesemia) and clinical (underlying seizure disorders,
hypertension) risk factors.20 Furthermore, reversible posterior
leukoencephalopathy due to oral CyA treatment in severe UC
has also been documented.21 The condition reversed onFigure 1 Pathophysiology of neurologic disorders in IBD.discontinuation of the drug and correction of the associated
factors.
The difference between oral and i.v. infusion of CyA is
another important issue. Because CyA is insoluble inwater, the
i.v. preparation is formulated in a polyoxyethylated castor oil
and ethyl alcohol. Rat dorsal root ganglion neurons exposed in
vitro to the i.v. preparation exhibited axonal swelling and
degeneration. No effect of CyA (dissolved directly in serum)
was seen on testing individual components of the i.v. solution.
However, 0.1% polyoxyethylated castor oil (volume of solute/
volume of solvent) produced axonal swelling and degeneration
and 0.001% polyoxyethylated castor oil produced demyelin-
ation in vitro. Polyoxyethylated castor oil is manufactured by
reacting castor oil with ethylene oxide, and it is speculated
that residual ethylene oxide or a polymerization product may
be responsible for the in vitro neurotoxicity. Although little is
known about the pharmacokinetics of polyoxyethylated castor
oil, plasma levels of 0.001 to 0.01% polyoxyethylated castor oil
(volume of solute/volume of solvent) are probably achieved
with therapeutic doses of the i.v. CyA preparation.22 Overall,
the Cosmetic Ingredient Review Expert Panel concluded that
these cosmetic ingredients are safe in the practices of use.
Therefore, no serious neurotoxicity of CyA could be attributed
to them.23
Metronidazole is an antibiotic drug commonly used in
patients with IBD, especially CD. Peripheral neuropathy is a
well-documented side effect of the drug, especially in cases
with daily dosages over 800 mg and for long periods of
time.24,25 In addition, metronidazole-induced neuropathy is
characterized by sensory phenomenology (with occasional
sensory ataxic features) with or without resolution after
discontinuation.14 The authors underscore the need to
closely monitor the neurologic status of patients undergoing
chronic treatment with metronidazole.
Sulfasalazine is a widely used and highly effective anti-
inflammatory agent in the treatment of CD and UC, also
being used with increasing frequency in the treatment of
various rheumatological disorders.26 Severe side effects such
as neurotoxicity necessitating discontinuation occur in less
than 5% of treated patients.27 The adverse effect of
sulfasalazine in causing folate deficiency has been well
documented previously.28 There are several reasons for this.
Firstly, the drug causes oxidative damage to red cells leading
to haemolysis and increased folate requirements. Secondly,
it can impair folate absorption in a competitive manner, by
inhibiting the jejunal hydrolysis of pteroylpolyglutamates
and thus the absorption of most dietary folates. In addition,
the drug has been shown to competitively inhibit three
enzymes involved in the metabolism of folic acid, namely
dihydrofolate reductase, serine transhydroxymethylase and
methylene tetrahydrofolate reductase.
Recently, monoclonal antibodies against anti-tumor
necrosis factor α (infliximab, adalimumab, certolizumab,
etanercept, onercept and others) and against α4 integrins
(natalizumab, MLN020) have been introduced in the treat-
ment of IBD.29–31 However, these therapies carry the risk of
severe adverse effects. The induction of lymphoma, oppor-
tunistic infections or reactivation of latent infections (e.g.
tuberculosis), demyelination and optic neuritis have been
reported.32–36 The increasing number of neurological com-
plications report on the association between anti-TNF-alpha
treatment and various disorders of peripheral nerve such as
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inflammatory demyelinating polyneuropathy, multifocal
motor neuropathy with conduction block, mononeuropathy
multiplex, and axonal sensorimotor polyneuropathies and
the temporal relationship of their occurrence to anti-TNFα
treatment support the contention that they are drug
induced.37 The exact mechanism(s) underlying such neurolog-
ical sequelae remain uncertain. The proposed pathogeneses of
TNF-alpha-associated neuropathies include both a T-cell and
humoral immune attack against peripheral nerve myelin,
vasculitis-induced nerve ischemia, and inhibition of signaling
support for axons.
Most neuropathies improve over a period of months by
withdrawal of the TNF-alpha antagonist, with or without
additional immune-modulating treatment. The proposed
pathogeneses of TNF-alpha-associated neuropathies include
both a T-cell and humoral immune attack against peripheral
nerve myelin, vasculitis-induced nerve ischemia, and inhibi-
tion of signaling support for axons. Most neuropathies
improve over a period of months by withdrawal of the TNF-
alpha antagonist, with or without additional immune-modu-
lating treatment. Even severe cases have been reported, such
as the case of a 40-year-old man with CD and acute paraplegia
four months after initiation of infliximab.38
The advent of progressive multifocal leukoencephalopa-
thy under the treatment with natalizumab is also particularly
noteworthy.39,40 Since several studies have independently
demonstrated an increased prevalence of non-neurologic
and neurologic autoimmune disorders amongst IBD, and
particularly UC-patients,41,42 a heightened awareness of
such unforeseen potential drug–disease interactions seems
mandatory.43 Some have advocated a brain MRI to look for
silent demyelination before initiating therapies of that kind.
This may become the standard in practice in the future.
The most commonly used medications responsible for
neurologic manifestations in IBD are summarized in Table 2.
1.3. Cranial nerve palsies
Cranial nerve palsies associated with CD have been previ-
ously reported44,45 in addition to ischemic optic neuropathy
and sensori-neural deafness. The Melkersson–Rosenthal
syndrome, characterized by recurrent facial nerve palsy,
fissuring of the tongue and non-caseating tissue granulomas,
has also been described in association with CD.46 Elsehety
et al. in their retrospective review of 263 patients with CD,
documented one case of sixth nerve palsy among otherTable 2 Commonly used medications responsible for
neurologic manifestations in IBD.
Agent Side effects
Sulfasalazine27,28 Peripheral neuropathy
Metronidazole14,24,25 Autonomic or sensory
peripheral neuropathy
Cyclosporine A16–23 Peripheral and central
neuropathy
αntiTNF-α (infliximab,
adalimumab, etch.)32–38
Mainly central neuropathy
(demyelination,
leukoencephalopathy, etch)
Numbers represent the relative references.neurological complications reported.2 The long intracranial
course of the sixth nerve predisposes to injury by a variety of
abnormalities. Karajeh et al. described the case of a 27-year-
old female smoker with a 12-day history of diplopia on right
lateral gaze associated with retro-orbital pain, preceding the
clinical diagnosis of CD.47 This clinical presentation is
compatible with vasculopathic sixth nerve palsy, which
typically presents with the sudden onset of a unilateral
abduction deficit accompanied by retro-orbital pain and
diplopia. Complete recovery is often observed and usually
occurs within 2–3 months. The microscopic neuroanatomy of
the sixth nerve reveals penetration by small nutrient vessels,
occlusion of which produces infarction. It is hypothesized
that microvascular ischemic demyelination of a portion of
the nerve is a most likely cause of vasculapathic sixth nerve
palsy. The area of ischemic demyelination subsequently
undergoes remyelination over time, precipitating clinical
recovery.48
Optic neuropathy presenting as bilateral optic disc
swelling is a rare complication associated in most cases
with CD.44,49,50 However, Romero Aroca P et al. reported the
case of 27-year old woman with UC and optic neuritis.51 The
ocular manifestations resolved when systemic mesalamine
was initiated. Previously reported cases have been attribut-
ed to peripapillary inflammation, optic disc ischaemia or
intracranial hypertension. Postulated causes of optic nerve
ischaemia include a local vasculitis or general hypercoagu-
lability. The underlying aetiology of intracranial hyperten-
sion is often elusive. Modern imaging emphasizes the need to
exclude dural venous sinus thrombosis, a serious cerebro-
vascular complication reported in both CD52–55 and UC.56,57
IBD can be associated with severe erosive arthritis that
affects the craniocervical junction.58 This process, although
infrequent, can result in severe neurological deficit if it is
not recognized. The possibility of occipitoatlantal involve-
ment in any inflammatory atlantoaxial subluxation must be
considered in the selection of treatment strategies.1.4. Other cerebrovascular conditions
Cerebrovascular disorders are documented in 0.12% to 4% of
IBD patients5 and apparently constitute the most extensively
covered neurologic complication, as they play a very impor-
tant role in disease morbidity. They occur at any age in both
sexes and tend to correlate with disease activity. Cerebral and
retinal arterial and venous circulation may be affected by a
hypercoagulability related thrombosis, vasculitis8,59,60 and
consumption coagulopathy leading to hemorrhagic events.61 It
has been shown that especially UC patients have a three to
fourfold increased risk of thromboembolism.62 It is unclear
whether primary venous or arterial strokes are more frequent.
With respect to the latter, large artery infarctions involving
the anterior and posterior circulation, as well as lacunar
infarcts have been described.63–66 Autochtonous thrombosis,
arterio-arterial and paradoxal embolism are possible patho-
geneses. Lately, an association of UC and thrombotic
cytopenic purpura with its risk for small and large artery
thrombosis has also been proposed.67
The pathophysiology of thrombosis in IBD patients is not fully
understood. Associated coagulation problems are thought to be
involved.These factors include thrombocytosis, increased levels
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factor III deficiency and free protein S deficiency.11,68 There is a
reported case of activated protein C resistance in a child with
CD, who developed a thromboembolic event.69 In many
reported cases there has been a link between steroid therapy
and the development of thrombogenesis, which is explained on
the basis of the antifibrinolytic action of the steroids,whichmay
have augmented the hypercoagulable state in these chil-
dren.11,70–72 A recent report confirms increases in fibrinogen,
prothrombin fragment F1+2, platelets, plasminogen activator
inhibitor-1 antigen and soluble thrombomodulin.73 Many of
these levels are higher during the active phase of the disease.
Besides these several coagulation abnormalities, attention has
recently been focused on antiphospholipid antibodies, including
anticardiolipin antibodies and lupus anticoagulant, hyperhomo-
cysteinemia and changes in the lipid spectrum,which have been
associated with a tendency to thrombus formation, particularly
in cerebral vasculature in young patients.72,74,75 In addition to
the factors leading to a hypercoagulable state, the disease
activity with possible quantitative as well as qualitative
platelet disorders, prolonged dehydration and immobilization
could contribute to the development of vascular complications
in IBD.
Multiple sclerosis (MS) has repeatedly been associated
with both UC8 and CD.76 Patients with IBD and successive
development of a MS-like disease as well as those with MS
and successive development of IBD have been described.77,78
A comorbidity between MS and CD was found by Beaugerie
et al. 79 in 4 of 832 patients. As central nervous system
vasculitis can complicate IBD, the differential diagnosis with
MS can be extremely difficult.
Whilst an association of epilepsy-seizure disorders and IBD
has been reported in some review articles,2,80 small case
series and case reports,81 none of these papers addresses the
question of a potential association of IBD and epilepsy
specifically. Moreover, if there were an association of
epilepsy and IBD, it seems to be preferentially with CD, not
with UC.2 Nevertheless, epileptic seizures in IBD patients
may occur in relation to structural or metabolic causes.5,63,82
The seizures may be generalized tonicoclonic, complex,
simple partial or even multiple. However, they are most
likely epiphenomena that have to be regarded symptomatic
rather than as neurologic manifestations of IBD, along with
confusional states and unspecified encephalopathies.1.5. Association with myopathies and other
conditions
Myasthenia Gravis (MG) has been reported to be associated
with both UC and CD. The link between IBD and MG is thought
to be related to the production of acetylocholine receptor
antibodies.83 However, autoimmune disorders, including
MG, occur more frequently in UC than in CD.84 MG is also
associated with other autoimmune diseases including alope-
cia, lichen planus, vitiligo and systemic lupus erythematosus.
Foroozan R et al. 85 reported the case of a 21-year old male
with ocular MG and UC, complaining for binocular diplopia
and ptosis of the left upper eyelid. He was hospitalized for
plasmapheresis and upon discharge treated with azathio-
prine, prednisone and mestinon. The symptoms resolved one
month later. Based on the few reports with ocular MG inpatients with IBD,5,83–88 the mean duration of IBD before the
diagnosis of MG was 10 years. Autoimmune dysregulation is
the central defect in both MG and IBD. Both IBD and MG may
be associated with an elevated carcinoembryonic antigen
(CEA) and decreased peripheral lymphocyte counts that
subsequently normalise following thymectomy.89 Some
studies have shown abnormal thymic involution and the
presence of an abnormal ratio of T suppressor to T helper
cells in both MG and UC, while others have noted a decline in
suppressor T cells and an increase in immature T cells
suggesting migration without normal maturation.90,91 The
immunological link between MG and IBD is highlighted by
reports of patients undergoing surgical treatment. One
report of a patient with both MG and CD documented
improvement in perineal and perianal disease following
thymectomy for severe uncontrolled MG.84 Another patient
with both MG and UC demonstrated regression of the
myasthenia following proctocolectomy.87 Although the si-
multaneous occurrence of these two autoimmune disorders
is uncommon, it is important to understand that ocular
findings may be the initial manifestation of MG in patients
with IBD.
Granulomatous myositis and myopathy associated not
only with CD92,93 but also with UC94 have been reported
previously, most of them during an acute exacerbation of the
disease.95 Gilliam et al. described a case of leukocytoclastic
vasculitis involving muscle associated with CD colitis.96 Most
cases of polymyositis and pyomyositis have been associated
mainly with CD,97,98 even if single cases associated with UC
have also been reported.99
Spinal epidural abscess (SEA) is a rare but well-established
and serious neurological complication of CD.100 Both immu-
nosuppressive treatment strategies including chronic ster-
oids and the presence of intra-abdominal or retroperitoneal
fistulas represent factors that predispose for the develop-
ment of SEA. A high index of suspicion is needed, as early
diagnosis can lead to a better clinical outcome. Back pain
that follows a flare-up of CD with and without obvious
neurological signs may be the result of inflamed paraverteb-
ral and spinal structures and can serve as an early sign of
SEA.101 SEA is a neurosurgical emergency in the setting of
intolerable pain and/or progressive neurologic deteriora-
tion, particularly involving bowel or bladder function.
Patients with SEA associated with CD often require a
combination of medical and surgical therapy, in addition to
a workup for and definitive treatment of bowel fistulas and
psoas abscesses, hopefully to prevent recurrences. Pro-
longed use of antibiotics is recommended even if cultures do
not yield causative organisms.
In addition, myeloradiculitis caused by Cryptococcus
neoformans in a patient with UC has been reported, thus
indicating that it should be included in the differential
diagnosis of acute onset myeloradiculopathy, especially in
cases of immunocompromised hosts.102 Lymphocytic ence-
phalomyeloneuritis and UC103 and focal white matter lesions
in IBD patients have been described.104 In patients with CD
CNS tumors have also been reported (glioblastoma multi-
forme, cholesteatoma, spinal meningioma).
Other symptoms such as classic migraine, musculoskeletal
headache, tension headache, Parkinson-like syndrome,
dystonia, cerebellar syndrome, organic brain syndrome,
chronic fatigue syndrome, urinary incontinence, orbital
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been reported in patients with IBD.2
Finally, an association of IBD and especially UC with
atypical vestibular system disorders such as dizziness,
vertigo, nausea and temporary loss of equilibrium has also
been described.8 In addition, sensorineural hearing loss, a
probable immunologic manifestation of IBD, has been
reported in both diseases.105–108 The clinical manifestation
of the disease is most often bilateral and progressive. The
hearing level often fluctuates, with periods of deterioration
alternating with partial or even complete remission. The
tendency is for the gradual evolution of permanent hearing
loss, which usually stabilizes with some remaining auditory
function but occasionally proceeds to complete deafness.
Vestibular dysfunction, particularly disequilibrium and pos-
tural instability, may accompany the auditory symptoms.2. Discussion
It seems that neurologic manifestations of IBD consider a
major health problem, affecting disease morbidity. There is
evidence that UC and CD can manifest both in the PNS and in
the CNS. It seems that involvement of the PNS occurs mostly
in UC, whereas myopathy and myelopathy characterize CD.
Direct extension of inflammatory masses or abscesses into
the surrounding tissues is characteristic of CD. MS cannot be
definitely ruled out in the patients with myeplopathy.
Nutritional deficiencies, and medications seem to play an
important role in the development of neurological manifes-
tations in patients with IBD.
Thromboembolism is a serious complication of IBD
patients that may be sudden and fatal. Thromboses of the
lower extremities and pelvic veins are most common, but
complications may also present as strokes in young patients
without evidence of atherosclerotic disease. Intravascular
thrombosis in mucosal blood vessels may play a role in the
pathogenesis of IBD. Some studies indicate that heparin may
benefit the treatment of IBD.109,110 The risk factors,
relationship between disease activity, corticosteroid use
and thrombotic events, and incidence of concomitant
coagulation disorders on thrombosis in IBD patients are still
not completely understood. Nowadays, IBD patients are less
frequently hospitalized and immobilized. This may be the
reason why the current incidence of thrombotic complica-
tions is lower.111
Although the mechanisms involved in the pathogenesis of
neurologic manifestations of IBD are not clear, it is probably
related to a common dysimmune basis, affecting cell-
mediated and humoral immunity and inflammatory mechan-
isms.5 In addition, infection by microbial agents, namely
Campylobacter jejuni, is linked to exacerbations of IBD and
may contribute to the development of autoimmune inflam-
matory demyelinating polyneuropathy.112
It has been known that some neurological manifestations
may correlate with several parameters of IBD, such as
extent, type and duration of disease. In addition, they
usually parallel the activity of intestinal inflammation.
In conclusion, the association of neurologic disorders with
IBD is probably more common than appreciated and may
follow a different pattern of involvement in UC and CD. Small
numbers currently preclude a better characterization of theclinical spectrum and a better understanding of pathogen-
esis. A prospective, controlled population-based study is
required to further elucidate the interrelationship between
IBD and neurologic manifestations.
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